4.7 Article

Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models

Journal

Publisher

MDPI
DOI: 10.3390/ijms21124493

Keywords

intratumoral; dispersion; diffusion; cytotoxic; cisplatin; vinblastine; cell-penetration; enhancer; immune activation; PD-1; antibody; CTLA-4; checkpoint

Funding

  1. Intensity Therapeutics

Ask authors/readers for more resources

The recent development of immune-based therapies has improved the outcome for cancer patients; however, adjuvant therapies remain an important line of treatment for several cancer types. To maximize efficacy, checkpoint inhibitors are often combined with cytotoxic agents. While this approach often leads to increased tumor regression, higher off target toxicity often results in certain patients. This report describes a novel formulation comprising a unique amphiphilic molecule, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO), that non-covalently interacts with payloads to increase drug dispersion and diffusion when dosed intratumorally (IT) into solid tumors. SHAO is co-formulated with cisplatin and vinblastine (referred to as INT230-6). IT dosing of the novel formulation achieved greater tumor growth inhibition and improved survival in in vivo tumor models compared to the same drugs without enhancer given intravenously or IT. INT230-6 treatment increased immune infiltrating cells in injected tumors with 10% to 20% of the animals having complete responses and developing systemic immunity to the cancer. INT230-6 was also shown to be synergistic with programmed cell death protein 1 (PD-1) antibodies at improving survival and increasing complete responses. INT230-6 induced significant tumor necrosis potentially releasing antigens to induce the systemic immune-based anti-cancer attack. This research demonstrates a novel, local treatment approach for cancer that minimizes systemic toxicity while stimulating adaptive immunity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Oncology

INT230-6, a novel intratumoral anticancer agent, is able to eradicate large established tumors and stimulate potent anti tumor immunity

Ian B. Walters, Lewis H. Bender, Masaki Terabe, Jay A. Berzofsky

CANCER RESEARCH (2015)

Meeting Abstract Oncology

A novel immunotherapy, INT230-6, is able to induce high rates of complete response in mice through a cytotoxic T-cell-dependent mechanism

Ian B. Walters, Anja C. Bloom, Lewis H. Bender, Masaki Terabe, Jay A. Berzofsky

CANCER RESEARCH (2016)

Meeting Abstract Oncology

Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies.

Yada Kanjanapan, Nilofer Saba Azad, Lillian L. Siu, Anthony J. Olszanski, Ian B. Walters, Lisa Kamen, Lewis H. Bender, Anthony B. El-Khoueiry

JOURNAL OF CLINICAL ONCOLOGY (2018)

Meeting Abstract Oncology

Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation.

Anthony B. El-Khoueiry, Jacob Stephen Thomas, Diana L. Hanna, Lillian L. Siu, Nilofer Saba Azad, Giles Francis Whalen, Lewis H. Bender, Ian B. Walters, Anthony J. Olszanski

JOURNAL OF CLINICAL ONCOLOGY (2019)

Article Oncology

Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

Anja C. Bloom, Lewis H. Bender, Shweta Tiwary, Lise Pasquet, Katharine Clark, Tianbo Jiang, Zheng Xia, Aizea Morales-Kastresana, Jennifer C. Jones, Ian Walters, Masaki Terabe, Jay A. Berzofsky

ONCOIMMUNOLOGY (2019)

Meeting Abstract Oncology

Tumor cell death caused by INT230-6 induces protective T cell immunity

Anja C. Bloom, Lewis H. Bender, Ian B. Walters, Katharine T. Clark, Masaki Terabe, Jay A. Berzofsky

CANCER RESEARCH (2017)

Meeting Abstract Hematology

Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects

Shaker A. Mousa, Haifeng Zhang, Ahmad Aljada, Fuming Zhang, Ehud Arbit, Lewis Bender, Michael Goldberg, Robert Linhardt

BLOOD (2007)

No Data Available